Background: Graves' disease is the most common cause of hyperthyroidism in children. Delay in the diagnosis and treatment of hyperthyroidism in children is associated with neurodevelopmental disorders, changes in bone maturation, decreased school performance, drastic weight loss. Three treatment options include antithyroid drugs, surgery, and radiation. The initial treatment regimen is the use of the antithyroid drug thiamazole subtype. Objective: The aim of this study was to determine the effect of tiamazol administration on changes in body weight in children with Graves' disease Methode: This study is a retrospective cohort analytic using medical record data on all children aged 1?18 years according to the inclusion criteria. The subject's medical record data was requested from the Medical Record Installation by showing the research permit. Subject data, namely characteristics including gender, child's age, year of arrival, nutritional status (weight, height) and thyroid profile (T4, TSH). Data analysis was carried out using the SPSS version 20.0 program with dependent t test and wilcoxon test. The difference was considered significant if p < 0.05 Result : A total of 32 subjects in this study according to the inclusion criteria. There were significant differences in weight, height and mass index at the first and second visits with p<0.05. There was a significant change in baseline T4 levels compared to visit I and visit II with p<0.05, while the difference in the mean change in baseline TSH levels at visits I and II was not significant (p>0.05). Conclusion : Tiamazole administration caused changes in free T4 levels in the blood in the third and sixth months, but changes in TSH levels were not significant at the sixth month.

children

Graves Disease

nutritional status

thiamazole

children